SEARCH

SEARCH BY CITATION

References

  • Aggarwal, A., Schneider, D.J., Terrien, E.F., Terrien, Jr, C.M., Sobel, B.E. & Dauerman, H.L. (2003) Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting. American Journal of Cardiology, 91, 13461349.
  • Ataga, K.I. & Orringer, E.P. (2003) Hypercoagulability in sickle cell disease: a curious paradox. American Journal of Medicine, 115, 721728.
  • Azar, R.R., Kassab, R., Zoghbi, A., Aboujaoude, S., El Osta, H., Ghorra, P., Germanos, M. & Salame, E. (2006) Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. American Heart Journal, 151, 521.
  • Belcher, J.D., Marker, P.H., Weber, J.P., Hebbel, R.P. & Vercellotti, G.M. (2000) Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood, 96, 24512459.
  • Berney, S.I., Ridler, C.D., Stephens, A.D., Thomas, A.E. & Kovacs, I.B. (1992) Enhanced platelet reactivity and hypercoagulability in the steady state of sickle cell anaemia. American Journal of Hematology, 40, 290294.
  • Brittain, J.E., Mlinar, K.J., Anderson, C.S., Orringer, E.P. & Parise, L.V. (2001) Activation of sickle red blood cell adhesion via integrin-associated protein/CD47-induced signal transduction. Journal of Clinical Investigation, 107, 15551562.
  • Byzova, T.V. & Plow, E.F. (1997) Networking in the hemostatic system. Integrin alphaIIbbeta3 binds prothrombin and influences its activation. Journal of Biological Chemistry, 272, 2718327188.
  • Curran, M.P. & Keating, G.M. (2005) Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs, 65, 20092035.
  • Dale, G.L., Friese, P., Batar, P., Hamilton, S.F., Reed, G.L., Jackson, K.W., Clemetson, K.J. & Alberio, L. (2002) Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature, 415, 175179.
  • Frishman, W.H. & Grewall, P. (2000) Serotonin and the heart. Annals of Medicine, 32, 195209.
  • Furman, M.I., Krueger, L.A., Linden, M.D., Barnard, M.R., Frelinger, III, A.L. & Michelson, A.D. (2004) Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. Journal of the American College of Cardiology, 43, 23192325.
  • Furman, M.I., Krueger, L.A., Linden, M.D., Fox, M.L., Ball, S.P., Barnard, M.R., Frelinger, III, A.L. & Michelson, A.D. (2005) GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Journal of Thrombosis and Haemostasis, 3, 312320.
  • Hebbel, R.P., Osarogiagbon, R. & Kaul, D. (2004) The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation, 11, 129151.
  • Heeschen, C., Dimmeler, S., Hamm, C.W., Van Den Brand, M.J., Boersma, E., Zeiher, A.M. & Simoons, M.L. (2003) Soluble CD40 ligand in acute coronary syndromes. New England Journal of Medicine, 348, 11041111.
  • Heitzer, T., Ollmann, I., Koke, K., Meinertz, T. & Munzel, T. (2003) Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease. Circulation, 108, 536541.
  • Henn, V., Slupsky, J.R., Grafe, M., Anagnostopoulos, I., Forster, R., Muller-Berghaus, G. & Kroczek, R.A. (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature, 391, 591594.
  • Keating, F.K., Dauerman, H.L., Whitaker, D.A., Sobel, B.E. & Schneider, D.J. (2006) Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. Thrombosis Research, 118, 361369.
  • Key, N.S., Slungaard, A., Dandelet, L., Nelson, S.C., Moertel, C., Styles, L.A., Kuypers, F.A. & Bach, R.R. (1998) Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood, 91, 42164223.
  • Kuypers, F.A., Lewis, R.A., Hua, M., Schott, M.A., Discher, D., Ernst, J.D. & Lubin, B.H. (1996) Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled annexin V. Blood, 87, 11791187.
  • Lee, Y., Lee, W.H., Lee, S.C., Ahn, K.J., Choi, Y.H., Park, S.W., Seo, J.D. & Park, J.E. (1999) CD40L activation in circulating platelets in patients with acute coronary syndrome. Cardiology, 92, 1116.
  • Lee, S.P., Ataga, K.I., Orringer, E.P., Phillips, D.R. & Parise, L.V. (2006) Biologically active CD40 ligand is elevated in sickle cell anemia. Potential role for platelet-mediated inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 16261631.
  • Marcondes, S., Lafay, M., Brohard-Bohn, B., De Nucci, G. & Rendu, F. (2000) Platelets induce human umbilical vein endothelial cell proliferation through P-selectin. Life Sciences, 66, 18171826.
  • Massberg, S., Mueller, I., Besta, F., Thomas, P. & Gawaz, M. (2003) Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting. American Heart Journal, 146, E19.
  • Matsui, N.M., Borsig, L., Rosen, S.D., Yaghmai, M., Varki, A. & Embury, S.H. (2001) P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. Blood, 98, 19551962.
  • Michelson, A.D. (2000) Flow cytometric analysis of platelets. Vox Sanguinis, 78(Suppl. 2), 137142.
  • Moser, M., Bertram, U., Peter, K., Bode, C. & Ruef, J. (2003) Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. Journal of Cardiovascular Pharmacology, 41, 586592.
  • Nannizzi-Alaimo, L., Alves, V.L. & Phillips, D.R. (2003) Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation, 107, 11231128.
  • Nylaende, M., Kroese, A., Stranden, E., Morken, B., Sandbaek, G., Lindahl, A.K., Arnesen, H. & Seljeflot, I. (2006) Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease. Vascular Medicine, 11, 2128.
  • O'Shea, J.C., Buller, C.E., Cantor, W.J., Chandler, A.B., Cohen, E.A., Cohen, D.J., Gilchrist, I.C., Kleiman, N.S., Labinaz, M., Madan, M., Hafley, G.E., Califf, R.M., Kitt, M.M., Strony, J. & Tcheng, J.E. (2002) Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. The journal of American Medical Association, 287, 618621.
  • Oliver, K.G., Kettman, J.R. & Fulton, R.J. (1998) Multiplexed analysis of human cytokines by use of the FlowMetrix system. Clinical Chemistry, 44, 20572060.
  • Palabrica, T., Lobb, R., Furie, B.C., Aronovitz, M., Benjamin, C., Hsu, Y.M., Sajer, S.A. & Furie, B. (1992) Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature, 359, 848851.
  • Papadimitriou, C.A., Travlou, A., Kalos, A., Douratsos, D. & Lali, P. (1993) Study of platelet function in patients with sickle cell anemia during steady state and vaso-occlusive crisis. Acta Haematologica, 89, 180183.
  • Phillips, D.R. & Agin, P.P. (1977) Platelet membrane defects in Glanzmann's thrombasthenia. Evidence for decreased amounts of two major glycoproteins. Journal of Clinical Investigation, 60, 535545.
  • Platt, O.S. (2000) Sickle cell anemia as an inflammatory disease. Journal of Clinical Investigation, 106, 337338.
  • Prasad, K.S., Andre, P., Yan, Y. & Phillips, D.R. (2003) The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease. Current Opinion in Hematology, 10, 356361.
  • Puma, J.A., Banko, L.T., Pieper, K.S., Sacchi, T.J., O'Shea, J.C., Dery, J.P. & Tcheng, J.E. (2006) Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the enhanced suppression of the platelet IIb/IIIa receptor with integrilin therapy (ESPRIT) trial. Journal of the American College of Cardiology, 47, 715718.
  • Savage, B., Saldivar, E. & Ruggeri, Z.M. (1996) Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell, 84, 289297.
  • Scholz, T., Zhao, L., Temmler, U., Bath, P., Heptinstall, S. & Losche, W. (2002) The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro. Platelets, 13, 401406.
  • Schonbeck, U. & Libby, P. (2001) The CD40/CD154 receptor/ligand dyad. Cellular Molecular Life Science, 58, 443.
  • Schonbeck, U., Mach, F. & Libby, P. (2000) CD154 (CD40 ligand). International Journal of Biochemistry and Cell Biology, 32, 687693.
  • Schonbeck, U., Varo, N., Libby, P., Buring, J. & Ridker, P.M. (2001) Soluble CD40L and cardiovascular risk in women. Circulation, 104, 22662268.
  • Setty, B.N., Kulkarni, S., Rao, A.K. & Stuart, M.J. (2000) Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation. Blood, 96, 11191124.
  • Shet, A.S., Aras, O., Gupta, K., Hass, M.J., Rausch, D.J., Saba, N., Koopmeiners, L., Key, N.S. & Hebbel, R.P. (2003) Sickle blood contains tissue factor positive microparticles derived from endothelial cells and monocytes. Blood, 102, 26782683.
  • Solovey, A., Kollander, R., Shet, A., Milbauer, L.C., Choong, S., Panoskaltsis-Mortari, A., Blazar, B.R., Kelm, Jr, R.J. & Hebbel, R.P. (2004) Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood, 104, 840846.
  • Tcheng, J.E. (1997) Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to minimize platelet aggregation and coronary thrombosis. American Journal of Cardiology, 80, 21B28B.
  • Tcheng, J.E., Harrington, R.A., Kottke-Marchant, K., Kleiman, N.S., Ellis, S.G., Kereiakes, D.J., Mick, M.J., Navetta, F.I., Smith, J.E. & Worley, S.J. (1995) Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation, 91, 21512157.
  • Welt, F.G., Rogers, S.D., Zhang, X., Ehlers, R., Chen, Z., Nannizzi-Alaimo, L., Phillips, D.R. & Simon, D.I. (2004) GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 61, 185189.
  • Yip, H.K., Chang, L.T., Sun, C.K., Yang, C.H., Hung, W.C., Cheng, C.I., Chua, S., Yeh, K.H., Wu, C.J. & Fu, M. (2006) Impact of clopidogrel on suppression of circulating levels of soluble CD40 ligand in patients with unstable angina undergoing coronary stenting. American Journal of Cardiology, 97, 192194.